-+ 0.00%
-+ 0.00%
-+ 0.00%

REVOLUTION MEDICINES BEGINS TREATING PATIENTS IN PHASE 3 RASOLUTE 309 TRIAL EVALUATING RASONQUE™ (DARAXONRASIB) PLUS ZOLDONRASIB AS FIRST-LINE TREATMENT FOR METASTATIC RAS G12D PANCREATIC CANCER

Reuters·10/05/2026 12:00:03

Please log in to view news